DF/HCC Program Affiliation

Prostate Cancer

Research Abstract

Dr. Garnick's predominant interest is urologic cancer, with a specialization in clinical investigation related to prostate cancer. Dr. Garnick is co-director of the Barry Hershey Foundation. In addition to his academic affiliation with Harvard Medical School and the Beth Israel Deaconess Medical Center, he is Chief Medical Officer and the Executive Vice President of PRAECIS Pharmaceuticals, Inc. where he is involved with the clinical development of a novel and potent GnRH antagonist, Abarelix.

Publications

View All Publications